


### AMENDMENTS TO THE CLAIMS

**Claim 1 (original):** Substituted 9a-N- {N'- [4- (sulfonyl) phenylcarbamoyl]} derivatives of 9-deoxo-9- - dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosamynil-9-deoxo-9-dihydro- -9a-aza-9a-homoerithronolide A of the general formula 1,



wherein R represents H or cladinosyl moiety, and R<sub>1</sub> represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3- - isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids.

**Claim 2 (original):** A substance according to claim 1, characterized in that R<sub>1</sub> represents chloro group and R represents cladinosyl moiety.

**Claim 3 (original):** A substance according to claim 1 characterized in that R represents chloro group, and R represents H.

**Claim 4 (original):** Substance according to claim 1 where R<sub>1</sub> represents amino group, and R represents cladinosyl moiety.

**Claim 5 (original):** A substance according to claim 1, characterized in that R<sub>1</sub> represents phenylamino group, and R represents cladinosyl group.

**Claim 6 (original):** A substance according to claim 1, characterized in that R<sub>i</sub> represents 2- - pyridylamino group, and R represents cladinosyl group.

**Claim 7 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents 3,4- dimethyl- -5-isoxazolyl group, and R represents cladinosyl moiety.

**Claim 8 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents 5-methyl- 3- - isoxazolylamino group, and R represents cladinosyl group.

**Claim 9 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents amino group and R represents H.


**Claim 10 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents phenylamino group, and R represents H.

**Claim 11 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents 2- - pyridylamino group, and R represents H.

**Claim 12 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents 3,4- dimethyl- -5-isoxazolylamino group, and R represents H.


**Claim 13 (original):** A substance according to claim 1, characterized in that R<sub>l</sub> represents 5- methyl-3- - isoxazolylamino group and R represents H.

**Claim 14 (original):** A process for the preparation of substituted 9a-N- {N'- [4- (sulfonyl) phenyl carbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O- desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1,




1

wherein R<sub>1</sub> represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, characterized in that 9a-N- {N'- [4- (chlorosulfonyl) phenyl]- carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5- - 0-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 1, wherein R<sub>1</sub> represents chloro group and R represent H or cladinosyl group, which can be prepared by reaction of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 2



2

wherein R represents H or cladinosyl group with 4- (chlorosulfonyl) phenyl isocyanate formula 3,



3

are subjected to a reaction with ammonia or amine of general formula 4,



4

R<sup>2</sup>-NH<sub>2</sub> 4 wherein R<sup>2</sup> represents H or phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a temperature 0-110°C and then, if appropriate, to a reaction with inorganic or organic acids.

**Claim 15 (original):** Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the substances according to claim 1.

**Claim 16 (currently amended):** A use of a substance of according to any claims 1-13 for preparing compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings.

**Claim 17 (new):** A method for inhibiting bacterial growth in vitro on a surface or in a substance comprising applying to said surface or substance a bactericidally effective amount of a compound according to claim 1.

**Claim 18 (new):** The method of claim 17 wherein the surface is selected from the group consisting of a wall, a room, a medical instrument.

**Claim 19 (new):** The method of claim 17 wherein the substance is selected from the group of wall coatings and wooden coatings.